A simple, rapid, isocratic, stability-indicating reverse phase ultra-performance liquid chromatographic (RP-UPLC) method was developed and validated for the routine analysis of moxonidine in the presence of its degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. Forced degradation studies were performed according to the guidance of International Conference for Harmonization and were used to evaluate moxonidine intrinsic stability. The drug was subjected to acid, neutral and base hydrolysis as well as to oxidative, thermal and photolytic decomposition in both solution and solid state. The drug appeared to be unstable towards acid and base hydrolysis. To achieve desirable conditions for UPLC analysis, the method development was done with the assistance of experimental design and multivariate optimization methodology by means of Derringer’s desirability function. Stress samples were analyzed according to the experimental plan for fractional factorial screening design and Box-Behnken optimization design. The chromatographic separation was achieved on a C18 Hypersil Gold aq. column (100 mm × 2.1 mm, 1.9 μm) with the mobile phase consisting of methanol–ammonium acetate buffer (10 mM, pH 3.43) mixture (0.9:99.1, v/v) pumped at a flow rate of 870 μL min−1 and detection wavelength of 255 nm. The UPLC–MS and UPLC–MS/MS analyses were further used to characterize the found degradation products. The validation of the proposed method was also performed considering selectivity, linearity, accuracy, precision, limit of detection and limit of quantification, and the results indicated that the method fulfilled all required criteria. The method was successfully applied to the analysis of commercial tablets.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Ziegler D, Haxhiu MA, Kaan EC, Papp JG, Ernsberger P (1996) J Cardiovasc Pharm 27:S26–S37
European Pharmacopoeia, (2011) 7th edn.
British Pharmacopoeia (2011)
Zhao L, Ding L, Wei X (2006) J Pharm Biomed Anal 40:95–99
Rudolph M, Janssen W, Strassner M (1992) J Pharm Biomed Anal 10:323–328
Milovanović S, Otašević B, Zečević M, Živanović LJ, Protić A (2012) J Pharm Biomed Anal 59:151–156
Kakde R, Gadpayale K, Qureshi MO (2012) Int J PharmTech Res 4(1):358–363
ICH topic Q1A(R2) (2003) Stability testing on new drug substances and products. Fed Regist 68:65717–65718
Kumar A, Saini G, Nair A, Sharma R (2012) Acta Pol Pharm Drug Res 69:371–380
Brereton RG (2003) Chemometrics—data analysis for the laboratory and chemical plant. Wiley, Chichester
Ortiz MC, Herrero A, Sanllorente S, Reguera C (2005) Talanta 65:246–254
Safa F, Hadjmohammadi MR (2005) J Chromatogr A 1078:42–50
Bakshi M, Singh S (2002) J Pharm Biomed Anal 28:1011–1040
Wren SAC, Tchelitcheff P (2006) J Chromatogr A 1119:140–146
Ferreira SLC, Brun RE, Paranhos da Silva EG, Lopes dos Santos WN, Quintella CM, David JM, Bittencourt de Andrade J, Breitkreitz MC, Jardim ICSF, Neto BB (2007) J Chromatogr A 1158:2–14
ICH topic Q2(R1) (1997) Validation of analytical procedures: text and methodology. Fed Regist 62: 27463–27467 (addendum incorporated 2005)
Araujo P (2009) J Chromatogr B 877:2224–2234
Nováková L, Matysová L, Solich P (2006) Talanta 68:908–918
This research was supported by the Ministry of science and technological development of Republic of Serbia as the part of the project no. 172033.
About this article
Cite this article
Otašević, B., Milovanović, S., Zečević, M. et al. UPLC Method for Determination of Moxonidine and Its Degradation Products in Active Pharmaceutical Ingredient and Pharmaceutical Dosage Form. Chromatographia 77, 109–118 (2014). https://doi.org/10.1007/s10337-013-2580-x
- Experimental design
- Multivariate optimization
- Forced degradation studies